An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes

M. Reni; H. Riess; E. O'Reilly; A. Santoro; J. Park; T. Bekaii-Saab; M. Tempero; Y. Shan; T. Macarulla; E. Van Cutsem; M. Noel; J. Berlin; A. Biankin; N. Dhani; G. Frassineti; D. Goldstein; A. Romano; Y. Le Bruchec; P. Philip

doi:10.1093/annonc/mdz154

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes

M. Reni, H. Riess, E. O'Reilly, A. Santoro, J. Park, T. Bekaii-Saab, M. Tempero, Y. Shan, T. Macarulla, E. Van Cutsem, M. Noel, J. Berlin, A. Biankin, N. Dhani, G. Frassineti, D. Goldstein, A. Romano, Y. Le Bruchec, P. Philip

Hematology/Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	iv126
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	30
DOIs	https://doi.org/10.1093/annonc/mdz154
State	Published - Jul 1 2019

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdz154

Cite this

Reni, M., Riess, H., O'Reilly, E., Santoro, A., Park, J., Bekaii-Saab, T., Tempero, M., Shan, Y., Macarulla, T., Van Cutsem, E., Noel, M., Berlin, J., Biankin, A., Dhani, N., Frassineti, G., Goldstein, D., Romano, A., Bruchec, Y. L., & Philip, P. (2019). An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Annals of oncology : official journal of the European Society for Medical Oncology, 30, iv126. https://doi.org/10.1093/annonc/mdz154

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. / Reni, M.; Riess, H.; O'Reilly, E. et al.
In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, 01.07.2019, p. iv126.

Research output: Contribution to journal › Article › peer-review

Reni, M, Riess, H, O'Reilly, E, Santoro, A, Park, J, Bekaii-Saab, T, Tempero, M, Shan, Y, Macarulla, T, Van Cutsem, E, Noel, M, Berlin, J, Biankin, A, Dhani, N, Frassineti, G, Goldstein, D, Romano, A, Bruchec, YL & Philip, P 2019, 'An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 30, pp. iv126. https://doi.org/10.1093/annonc/mdz154

Reni M, Riess H, O'Reilly E, Santoro A, Park J, Bekaii-Saab T et al. An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jul 1;30:iv126. doi: 10.1093/annonc/mdz154

Reni, M. ; Riess, H. ; O'Reilly, E. et al. / An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT) : primary analysis and quality of life outcomes. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2019 ; Vol. 30. pp. iv126.

@article{ce2353e756cd4745b7f56a7035289b42,

title = "An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes",

author = "M. Reni and H. Riess and E. O'Reilly and A. Santoro and J. Park and T. Bekaii-Saab and M. Tempero and Y. Shan and T. Macarulla and {Van Cutsem}, E. and M. Noel and J. Berlin and A. Biankin and N. Dhani and G. Frassineti and D. Goldstein and A. Romano and Bruchec, {Y. Le} and P. Philip",

year = "2019",

month = jul,

day = "1",

doi = "10.1093/annonc/mdz154",

language = "English (US)",

volume = "30",

pages = "iv126",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT)

T2 - primary analysis and quality of life outcomes

AU - Reni, M.

AU - Riess, H.

AU - O'Reilly, E.

AU - Santoro, A.

AU - Park, J.

AU - Bekaii-Saab, T.

AU - Tempero, M.

AU - Shan, Y.

AU - Macarulla, T.

AU - Van Cutsem, E.

AU - Noel, M.

AU - Berlin, J.

AU - Biankin, A.

AU - Dhani, N.

AU - Frassineti, G.

AU - Goldstein, D.

AU - Romano, A.

AU - Bruchec, Y. Le

AU - Philip, P.

PY - 2019/7/1

Y1 - 2019/7/1

UR - http://www.scopus.com/inward/record.url?scp=85079798591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85079798591&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz154

DO - 10.1093/annonc/mdz154

M3 - Article

C2 - 32085016

SN - 0923-7534

VL - 30

SP - iv126

JO - Annals of oncology : official journal of the European Society for Medical Oncology

JF - Annals of oncology : official journal of the European Society for Medical Oncology

ER -

An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this